First Timer here.
This stock hould be trading at 15.00 next week, see below:
1. Strong Cash Position to Continue to Execute on Business Plan with $106M in Cash, Equivalents, and Financing Receivable as of June 30, 2009
2. $8.1M in 2Q09 Revenue
3. 2Q09 ZEVALIN® Net Sales vs. 1Q09 ZEVALIN Net Sales Up 25%
4. Institutional Holdings - 37.7%
5. Short Interest As Of 7/31 - 12% of total float
6. 41.9M Shares Outstanding
7. FDA Decision on sBLA for ZEVALIN in First Line non-Hodgkin’s Lymphoma Expected by September 7th
8. FDA Decision on sNDA for FUSILEV™ in Metastatic Colorectal Cancer Expected by October 8th
9. * Strong Cash Position to Continue to Execute on Business Plan with $106M in Cash, Equivalents, and Financing Receivable as of June 30, 2009
10. On 8/6/09 SPPI announced they aquired full rights to RenaZorb, or SPI-014, which is a non-aluminum, non-polymer, non-calcium, lanthanum-based nanotechnology with highly potent and selective phosphate binding properties, for the potential treatment via oral administration, of hyperphosphatemia, (high phosphate levels in the blood), in patients with chronic kidney disease (CKD). Hyperphosphatemia in Stage 5 CKD, also known as end-stage renal disease (ESRD), can lead to significant bone disease (including pain and fractures), secondary hyperthyroidism in renal sufficiency, cardiovascular disease, and is independently associated with increased mortality. Currently marketed therapies for treating hyperphosphatemia include polymer-based and lanthanum-based phosphate binders, aluminum-based phosphate binders, and calcium-based phosphate binders. According to the United States Renal Data System (USRDS), over the last 20 years, the number of patients with ESRD in the US has grown 4-fold. By 2010 there will be an estimated 661,330 patients with ESRD.
11. The consensus held by most investors, analysts and commentators is that Zevalin will be approved as a first-line consolidation therapy for patients with NHL. It is important to note that Zevalin is already approved for use in the US for refractory NHL.
Institutional investors and hedge funds have been slow to catch on. With less than a a week to go before FDA review, SPPI remains a hidden gem. With a current price of $8.76 and a market cap of only $263 million, SPPI is well positioned to hit new multi-year highs in the coming weeks with Zevalin’s approval. As always do your own DD, but this stock is poised to continue it's ascension. GLTA
